Clinical Trial Update: Proximod, a Selective Sphingosine-1-phosphate Receptor 1 Modulator in Patients With Moderate-to-severe Active Rheumatoid Arthritis: a Double-blind, Randomised, Placebo-controlled, Phase 2 Trial. [Phase 2]

View source ↗

Summary

A Phase 2 double-blind, randomized, placebo-controlled trial evaluating Proximod, a selective S1P1 receptor modulator, in adults with moderate-to-severe active …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• Proximod

Snippet

Sponsor: Peking University People's Hospital | Conditions: Rheumatoid Arthritis | Phase 2 | Status: COMPLETED